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diseases and the leading cause of mortality worldwide. The
morbidity associated with diastolic heart failure (DHF;
including the rate of hospitalization) is similar to that
associated with systolic heart failure.1
In recent years, impaired calcium homeostasis of car-
diomyocytes was proposed to be one of the pathophysio-
logical hallmarks of DHF. Of numerous calcium-regulatory
proteins, decreased expression of sarcoplasmic reticulum
calcium ATP-ase 2 (ATPA2, SERCA2) and altered regulation
of phospholamban levels have been reported to correlate
with diastolic function.2,3 The combination of an enhanced
tissue renineangiotensin system (RAS) and hyperglycemia
leads to the development of fibrosis and myocyte hyper-
trophy, a prominent feature of DHF.2 In addition, our recent
study found that, through downregulation of SERCA2 gene
expression, inflammatory cytokines could cause cardiac
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to serum cytokine levels, but genetic studies of DHF are
scarce in the literature. In this article, we discuss recent
genetic studies related to the RAS gene, inflammatory gene
polymorphisms, and their relationship with DHF.
The ACE gene
Rigat et al first proposed that the D allele of the angiotensin
converting enzyme (ACE ) gene had a dose-dependent
influence in terms of plasma ACE concentration.4 The
concentration of plasma ACE is in proportion to the level of
hypertension or myocardial fibrosis, both of which are
important risks for DHF.
In 2008, we recruited 148 patients with DHF and controls
and found that the ACE gene I/D polymorphism was asso-
ciated with an increased risk of DHF. Subjects carrying two
copies of the D allele had an increased risk of DHF (odds
ratio 2.40, p Z 0.002).5 In addition, a synergistic interac-
tion of the ACE gene I/D polymorphism and an A1166C
polymorphism of the angiotensin II type 1 receptor AGTR1
gene on the risk of DHF was distinguished.
To further elucidate the possible mechanisms, we used
the propensity score to control left ventricular (LV) mass
and found that different ACE genotypes could predispose to
different pathways of development of DHF.6 The ACE gene& Formosan Medical Association. All rights reserved.
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mass in a well-matched cohort, whereas presence of the D
allele was strongly correlated with DHF after removing
patient matching for LV mass. The findings suggested that
ACE gene polymorphisms may affect DHF in different ways:
(1) the ACE II form may have an impact on angiotensin II
that then leads to LV hypertrophy and thus to the devel-
opment of DHF; (2) the ACE DD form may have a direct
trophic effect that leads to calcium overload or increased
myocardial stiffness, which further leads to DHF, indepen-
dent of LV hypertrophy.
The AGT gene
There was evidence that plasma AGT concentrations are
associated with genetic polymorphisms of the angiotensi-
nogen (AGT ) gene. We compared the differences among six
AGT gene polymorphisms [G-217A (rs5049), G-152A
(rs11568020), A-20C (rs5050), G-6A (rs5051), M235 T (rs699;
T4072C), and T174 M (rs4762; C3889 T)] in patients with DHF
and controls. Only the A-20Cpolymorphism of the AGT gene
was associated with an increased risk of DHF compared with
normal controls. However, the effect was not substantial
after multiple testing or after a comparison with risk-
matched controls.5,6 Haplotype analysis for the six-locus
haplotype of the AGT gene showed no significant difference
in the global haplotype profile in the above two studies.
The AGTR1 gene
An association study has been conducted in a Han Chinese
population. Eleven single nucleotide polymorphisms (SNPs)
tagging the AGTR1 gene were selected and analyzed.7 In
a single locus analysis, SNPs rs16860760, rs389566, and
rs5186 were shown to be associated with DHF. Also, SNP
rs389566, with a minor allele frequency of 20.17%, had anFigure 1 Possible mechanisms underlying genetic influences on
arrows Z downregulation.odds ratio of 2.03 for the autosomal dominant model
[AA þ AT: TT, 95% confidence interval (CI) 1.29e3.19;
p Z 0.0012] and 1.73 for the additive model (95% CI
1.21e2.48; p Z 0.0018), corresponding to a population
attributable risk fraction of 27.21%. The haplotypes in
a linkage disequilibrium block of rs389566 (T-A-G and A-A-
G) were also significantly associated with DHF after
permutation tests. The results revealed that, in addition to
A1166C polymorphisms (rs5186), the effects of other
genetic variants of the AGTR1 gene were significant for
DHF.
Genes associated with inflammation
Recent studies have concluded that the inflammatory
process arising from sepsis or even visceral adipose tissue
may lead to LV diastolic dysfunction.3,8 There are few re-
ported studies on inflammatory cytokine gene poly-
morphisms and DHF. Only one study has evaluated the
interleukin-10 gene (IL10) promoter polymorphism at posi-
tion e1082 and its association with conventional and
Doppler echocardiographic and tissue doppler imaging
parameters in 112 patients undergoing hemodialysis .9 The
authors concluded that the IL10 genotype may balance the
effects of inflammatory cytokines on the myocardium and
may be a determinant of LV function in hemodialysis
patients.
Pharmacogenetic effects
At present, there is little information about the prognostic
influence of RAS genes on DHF and the pharmacogenetic
interaction between the RAS gene and ACE inhibitors. We
followed a cohort of DHF patients for more than 10 years and
evaluated the genetic effects along with pharmacogenetic
interactions.10 In a multiple Cox regression model adjusteddiastolic heart failure. Black arrows Z upregulation; white
Gene polymorphisms and diastolic heart failure 71for the ACE inhibitor effect, the D allele of the ACE gene
induced a 2.04-fold hazard compared with the I allele, and
the AGTR1 A1166C C allele had a hazard ratio of 2.08
compared with the A allele. Moreover, in the group who
receivedACE inhibitors, theeffect of theACE geneDallele on
survival was no longer significant, suggesting a pharmacoge-
netic interaction. Therefore, genetic variation or poly-
morphisms in RAS genes are associated with not only the
development of DHF, but also long-term survival; however,
the effects can be modified by using ACE inhibitors.
Conclusions and future perspective
In conclusion, recent advances suggest that patients with
specific genetic variations in RAS or inflammatory genes
may be more likely to develop DHF (Fig. 1). The genetic
variants in the RAS genes were also associated with long-
term prognosis in DHF patients, but their effects could be
modified by the use of ACE inhibitors. By understanding the
pharmacogenetic effects related to treatment response,
patients who are most likely to benefit from such treatment
could be distinguished. This concept of therapy tailored by
pharmacogenetics may have a large impact on future clin-
ical practice.
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